|
- Lecanemab Bested Three Other Antibodies at Binding Soluble Aβ . . .
Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U S marketing approval What distinguished the successful ones? In a preprint posted to bioRxiv on October 12, scientists led
- Rising Leqembi Prescriptions Are Straining Clinic Capacity
As lecanemab use ramps up, clinicians expect demand to overwhelm the staff at most memory clinics At WashU’s Knight Alzheimer Disease Research Center—one of the larger centers in the country—the staff comprises 12 physicians and four physician assistants or nurse practitioners
- Dare We Say Consensus Achieved: Lecanemab Slows the Disease
The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement Now they have At the 15th Clinical Trials on Alzheimer’s Disease conference, held November 29 to
- Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
Lecanemab Secondary Prevention Study Now Fully Enrolled Lecanemab was approved for people with mild cognitive impairment or mild dementia due to Alzheimer’s, but trial data show it works better if given earlier The AHEAD 3-45 study, a pair of sister trials, homes in on this point, testing lecanemab’s ability to delay the onset of symptoms
- Leqembi Maintenance Dosing Approved in the U. S. | ALZFORUM
The U S Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27 Previously, the label called for biweekly IV dosing The new decision allows physicians to consider transitioning patients to monthly dosing once they have completed
- Questions, Questions for Donanemab, Lecanemab - ALZFORUM
For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they modeled how plaque clearance relates to cognitive benefit in an attempt to address a nagging question about this relationship See, You’re Negative
- Etalanetug - ALZFORUM
People with mild cognitive impairment or dementia will receive open-label intravenous lecanemab for 24 weeks, and then be randomized to intravenous E2814 or placebo plus lecanemab for the remainder of the four-year trial Participants with normal cognition will start on E2814 or placebo for one year, and then add open-label lecanemab
- Leqembi: The Case for Long-Term Dosing | ALZFORUM
Long-term lecanemab dosing in open-label extensions now goes out to three years, and continues to support the idea that the antibody slows disease progression On cognitive measures, the treatment group maintains its edge over the former placebo group, as is expected for a disease-modifying drug, and people at the earliest disease stages reap
|
|
|